85276-68-2

Upstream product

• 78238-12-7 3-methoxy-5-nitrobenzoic acid 
• 99-34-3 3,5-dinitrobenzoic acid 

Downstream Products

• 959163-14-5 N-ethoxy-3-methoxy-5-nitro-benzamide 
• 1050514-16-3 N-(2-hydroxyethyl)-3-methoxy-5-nitrobenzamide 
• 1509919-80-5 ethyl 3-(3-methoxy-5-nitrobenzamido)furo[2,3-b]pyridine-2-carboxylate 
• 1509919-87-2 3-(3-methoxy-5-nitrobenzamido)furo[2,3-b]pyridine-2-carboxamide 
• 1509919-94-1 2-(3-methoxy-5-nitrophenyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-4(3H)-one 
• 1509920-04-0 2-(3-methoxy-5-nitrophenyl)-4-(morpholin-4-yl)pyrido[3',2':4,5]furo[3,2-d]pyrimidine 
• 1509920-01-7 2-(3-methoxy-5-nitrophenyl)-4-(morpholin-4-yl)pyrido[3',2':4,5]furo[3,2-d]pyrimidine 
• 1509919-72-5 3-bromo-5-[4-(morpholin-4-yl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenol 
• 1509919-73-6 3-[4-(morpholin-4-yl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-5-nitrophenol 
• 269411-71-4 3-amino-5-methoxy-benzonitrile 
• 292635-40-6 3-methoxy-5-nitrobenzamide 
• 33224-19-0 3-methoxy-5-nitrobenzonitrile 
• 959163-15-6 3-amino-N-ethoxy-5-methoxy-benzamide 
• 959163-16-7 3-[(2,4-dichloro-pyrimidin-5-ylmethyl)-amino]-N-ethoxy-5-methoxy-benzamide 

Relevant academic research and scientific papers

PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the same, and a pharmaceutical use of the pyrimidine compound for the prevention or treatment of cancer.

Preparation technology of 3-cyano-5-anisole-1-sulfonyl chloride

The invention discloses a preparation technology of 3-cyano-5-anisole-1-sulfonyl chloride. The technology comprises the following steps: performing substitution reaction on a raw material which is 3,5-dinitrobenzene to obtain 3-anisyl-5-nitrobenzoic acid;

HETEROCYCLIC DERIVATIVES AND USE THEREOF

A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated with the activation of STAT3 protein.

Crystal structures of PI3Kα complexed with PI103 and its derivatives: New directions for inhibitors design

The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays important roles in cell proliferation, growth, and survival. Hyperactivated PI3K is frequently found in a wide variety of human cancers, validating it as a promising target for cancer therapy. We determined the crystal structure of the human PI3Kα-PI103 complex to unravel molecular interactions. Based on the structure, substitution at the R1 position of the phenol portion of PI103 was demonstrated to improve binding affinity via forming a new H-bond with Lys802 at the bottom of the ATP catalytic site. Interestingly, the crystal structure of the PI3Kα-9d complex revealed that the flexibility of Lys802 can also induce additional space at the catalytic site for further modification. Thus, these crystal structures provide a molecular basis for the strong and specific interactions and demonstrate the important role of Lys802 in the design of novel PI3Kα inhibitors.

QUINOXALINE COMPOUNDS AND USE THEREOF

The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS

Described are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent disease or disordered associated with abnormal or deregulated kinase activity, particularly diseases or disorders that